The size of the North American thyroid cancer market was valued at USD 121.35 million in 2022. This value is expected to grow at a CAGR of 24% and be worth USD 355.74 million by 2027.
The increasing number involving thyroid cancer-affected individuals and the rise in awareness within the supply of different therapy procedures are lavishing the growth regarding the thyroid cancer market in the North American region. Also, private and public organizations' rising investments in healthcare centers are fuelling the demand regarding the market inside North America.
Increasing government support by changing schemes and launching reimbursements for ordinary people will create market growth opportunities. However, thyroid cancer market growth is likely to be overshadowed by rising demand for high-quality treatment procedures and rising healthcare spending. One of the elements driving the development of the North American market is the expanding elderly population.
The therapy for thyroid disease includes significant expenses, which controls the market request gradually. Additionally, the expense of introducing and keeping up with the hardware is costly, which is an element restricting the interest of the market. Furthermore, the shortfall of talented people in medical procedures has remained a difficult element for market engineers. The absence of normalization may likewise thwart the development of the thyroid cancer market.
The COVID-19 impacted the North American thyroid disease diagnostics market adversely as the quantity of analyzed cases went down in 2020. In addition, the attention on COVID-19 brought about delays in disease screening, conclusion, and treatment due to diminished admittance to medical services.
This research report on the North American thyroid cancer market is segmented and sub-segmented into the following categories.
By Treatment:
By Drug:
By End User:
By Country:
Geographically, North America led the global thyroid cancer market in 2020 and is expected to continue to do so during the forecast period. The adoption of modern technologies and the introduction of novel approaches in healthcare centers propel the market forward. Rising capital income in developed and emerging countries is a shared element driving increased demand in this region. The market's demand is being widened by an older population and a resurgence in hospital scale. In addition, the market in this region is being driven by an increase in thyroid cancer cases and potential pipeline drugs to treat the disease.
Each year, over 35,000 women and 12,000 men are affected by thyroid cancer, with more than 1,100 women and 900 men dying from the disease. In 2016, the United States was expected to detect 64,000 new cases of thyroid cancer. Furthermore, the presence of top pharma and biotech companies working on innovative therapies and well-established healthcare infrastructure is supporting regional market expansion to a significant level.
KEY MARKET PLAYERS:
Companies playing a vital role in the North American thyroid cancer market profiled in this report are Baxter International Inc., Mylan Pharmaceuticals Inc., Alara Pharmaceutical Corporation, Bristol Myers co, Abbott laboratories, Teva parenteral medicines Inc., App pharmaceuticals LLC, and Jerome Stevens Pharmaceuticals Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Treatment
5.1.1 Introduction
5.1.2 Surgery
5.1.3 Iodine Theraphy
5.1.4 External radiotherapy
5.1.5 Thyroxine treatment
5.1.6 chemotherapy
5.1.7 Drugs
5.1.8 Y-o-Y Growth Analysis, By Treatment
5.1.9 Market Attractiveness Analysis, By Treatment
5.1.10 Market Share Analysis, By Treatment
5.2 End User
5.2.1 Introduction
5.2.2 Hospital
5.2.3 Oncology centers
5.2.4 Hospital Pharmacies
5.2.5 Retail Pharmacies
5.2.6 Y-o-Y Growth Analysis, By End User
5.2.7 Market Attractiveness Analysis, By End User
5.2.8 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Treatment
6.1.3.3 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Treatment
6.1.4.3 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Treatment
6.1.5.3 By End User
6.2 United States
6.3 Canada
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Baxter International Inc
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Mylan pharmaceuticals Inc
8.3 Alara Pharmaceutical Corporation
8.4 Bristol Myers co
8.5 Abbott laboratories
8.6 Teva parenteral medicines Inc
8.7 App pharmaceuticals llc
8.8 Jerome Stevens Pharmaceuticals Inc
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
